drugset
Drugs / cytotoxic lymphocytes
last change Dec 2020 re-read 2 minutes ago

cytotoxic lymphocytes

Cell therapy

Developed for
metastatic neoplasm
Investigated by
Blokhin's Russian Cancer Research Center · National Institute of Regenerative Medicine · NeuroVita Clinic · Russian Foundation of Technological Development · SRC Bioclinicum · The Serbsky State Scientific Center for Social and Forensic Psychiatry

Trials 1 · a red edge is where a trial was stopped

today NCT01782287 · Ph 2/3
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT01782287 Dec 2012 → Dec 2018 metastatic neoplasm NeuroVita Clinic Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT01759810 Background Dec 2012 → Dec 2018 glioblastoma NeuroVita Clinic Unknown No outcome recorded
Phase 2/3 NCT01782274 Comparator Dec 2012 → Dec 2018 metastatic neoplasm NeuroVita Clinic Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as cytotoxic lymphocytes ClinicalTrials.gov intervention name — accepted as the source's own label NCT01782287 ↗
2

NCT01759810 ↗

NCT01782274 ↗
Action Deplete “Preparation of CTLs aims to enhance cytotoxic effect on tumor due to great number of circulating CTLs.” NCT01782287 ↗
Modality Cell therapy “cytotoxic lymphocytes” NCT01759810 ↗
Route Intrathecal “Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months” NCT01759810 ↗